文献速递脊柱关节炎其他结缔组织病

银屑病、银屑病关节炎和中轴型脊柱关节炎患者不良COVID-19结局相关特征:来自COVID-19 PsoProtect和全球风湿病联盟医生报告登记处的数据

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
PubMed 文献 · Ann Rheum Dis · 2023-02-14

研究基于两个国际医生报告登记处的5045例银屑病、银屑病关节炎和中轴型脊柱关节炎成人患者,采用多变量有序逻辑回归分析COVID-19严重程度的相关因素。结果发现高龄、男性、合并症负担、较高疾病活动和糖皮质激素使用与更严重COVID-19相关,而较晚疫情时期、银屑病及TNFi、IL17i和IL-23i/IL-12+23i暴露与较轻COVID-19相关。

要点

  • 男性(OR 1.54,95%CI 1.30-1.83)及心血管、呼吸、肾脏、代谢和癌症合并症(OR 1.25-2.89)与更严重COVID-19相关。
  • 中/高疾病活动和/或使用糖皮质激素(OR 1.39-2.23,对比缓解/低疾病活动且未用糖皮质激素)与更严重COVID-19相关。
  • 较晚疫情时期(OR 0.42-0.52,对比截至2020年6月15日)、银屑病(OR 0.49,95%CI 0.37-0.65,对比银屑病关节炎)及TNFi、IL17i、IL-23i/IL-12+23i暴露(OR分别为0.57、0.62、0.67,对比未用改善病情抗风湿药)与较轻COVID-19相关。

核心结论

  • 高龄、男性、合并症负担、较高疾病活动和糖皮质激素摄入与更严重COVID-19相关。
  • 较晚疫情时期、银屑病及TNFi、IL17i和IL-23i/IL-12+23i暴露与较轻COVID-19相关。
  • 这些发现将有助于对银屑病、银屑病关节炎和中轴型脊柱关节炎患者进行风险分层并为管理决策提供信息。

研究设计与样本

  • 从两个国际医生报告登记处获取银屑病、银屑病关节炎和中轴型脊柱关节炎成人患者的人口学数据、临床特征和COVID-19结局严重程度。
  • 定义三点有序COVID-19严重程度量表:未住院、住院(且未死亡)和死亡。
  • 使用多变量有序逻辑回归估计OR值。

主要发现

  • 5045例中,18.3%为银屑病,45.5%为银屑病关节炎,36.3%为中轴型脊柱关节炎。
  • 83.6%未住院,14.6%住院,1.8%死亡。
  • 较高年龄与COVID-19严重程度呈非线性关联。
  • 男性(OR 1.54,95%CI 1.30-1.83)及心血管、呼吸、肾脏、代谢和癌症合并症(OR 1.25-2.89)与严重COVID-19 odds增加相关。
  • 中/高疾病活动和/或糖皮质激素使用(OR 1.39-2.23,对比缓解/低疾病活动且未用糖皮质激素)与严重COVID-19 odds增加相关。

临床怎么用

  • 作者认为这些发现将有助于对银屑病、银屑病关节炎和中轴型脊柱关节炎患者在COVID-19疫情波或未来类似呼吸道大流行期间进行风险分层并为管理决策提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Machado PM, Schäfer M, Mahil SK, et al. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann Rheum Dis. 2023. PMID: 36787993. doi:10.1136/ard-2022-223499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。